Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH

Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial

(2018) Renger G. Tiessen et al.   BMC GASTROENTEROLOGY

Role of Bile Acids in Metabolic Control

(2018) Antonio Molinaro et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis

(2018) Samer Al-Dury et al.   Scientific Reports

Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2017) Oscar Chávez-Talavera et al.   GASTROENTEROLOGY

Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial

(2017) Atsushi Nakajima et al.   JOURNAL OF GASTROENTEROLOGY

Biliary bile acids in hepatobiliary injury – What is the link?

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

(2017) Peter Fickert et al.   JOURNAL OF HEPATOLOGY

Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study

(2017) Vinod S Hegade et al.   LANCET

Review article: bile acid diarrhoea - pathogenesis, diagnosis and management

(2016) N. Mottacki et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

(2016) R. Pencek et al.   DIABETES OBESITY & METABOLISM

Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives

(2016) Juan P. Arab et al.   HEPATOLOGY

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis

(2016) Anna Baghdasaryan et al.   JOURNAL OF HEPATOLOGY

Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching

(2016) M.J. Mayo et al.   JOURNAL OF HEPATOLOGY

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

(2016) Frederik Nevens et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice

(2016) Anuradha Rao et al.   Science Translational Medicine

The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation

(2015) H. Graffner et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study

(2015) V. S. Hegade et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice

(2015) Alexander G. Miethke et al.   HEPATOLOGY

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid

(2014) J. R. F. Walters et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pleiotropic Roles of Bile Acids in Metabolism

(2013) Thomas Q. de Aguiar Vallim et al.   Cell Metabolism

Pruritus in cholestasis: Facts and fiction

(2013) Ulrich Beuers et al.   HEPATOLOGY

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions

(2012) Andreas E. Kremer et al.   HEPATOLOGY

Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study

(2011) M. Simrén et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of A3309, an Ileal Bile Acid Transporter Inhibitor, on Colonic Transit and Symptoms in Females With Functional Constipation

(2011) Banny S Wong et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation

(2011) William D Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus

(2010) Andreas E. Kremer et al.   GASTROENTEROLOGY

Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches

(2010) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome

(2009) L. WEDLAKE et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

(2009)   JOURNAL OF HEPATOLOGY